Potential Benefits of Incretins Beyond Glycemic Control in T2D

supported by an educational grant from Eli Lilly and Company |

13:00 – 13:05Welcome
Unmet Needs in T2D
Bernhard Ludvik (AUT)
13:05 – 13:20Delineating the Incretin Effect and the Roles of GLP-1 and GIP
Potential Benefits of Agonism of Multiple Receptors: Mechanism of Action of Unimolecular Dual Agonists
Michael A. Nauck (GER)
13:20 – 13:35

Clinical Implications of Dual Agonis Efficacy and Safety Data

Juan Pablo Frias (USA)
13:35 – 13:40Q&A

All faculty

13:40 – 13:50Case StudiesBernhard Ludvik (AUT)
13:50 – 14:00Ask Me Anything All faculty

Provided by Medical Learning Institute, Inc. and Endocrine Society